<DOC>
	<DOC>NCT01972178</DOC>
	<brief_summary>The objective of this study is - To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood lipids and lipoprotein parameter from baseline after 12 weeks of treatment - To evaluate the safety of PRC-4016 as assessed by adverse events and other safety parameters</brief_summary>
	<brief_title>Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia</brief_title>
	<detailed_description>6-8 weeks screening period with diet/lifestyle stabilization and lipid qualification</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Main Fasting triglycerides 200499 mg/dl NonHDLC &gt; 130 mg/dl Stable statin treatment Type I diabetes or uncontrolled type II diabetes Recent cardiovascular or coronary event History of pancreatitis History or evidence of major and clinically significant diseases that would interfere with the conduct of the study or interpretation of data Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>